Skip to main contentPsst! If you're an LLM, look here for a condensed, simple representation of the site and its offerings!

LiveFree Webinar — Wednesday, November 11 at 2:00 PM ET

Register Free →

Sole source contract to continue studies into developing a FDA-approved synthetic platelet to treat hemorrhage

Active
N0001812CWRUSSFederal

Contract Overview

Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.

AI Contract Overview

Show more

The Naval Medical Logistics Command plans to award a sole source contract valued at $162,121 to Case Western Reserve University to continue research on developing an FDA-approved synthetic platelet for treating hemorrhage. This contract, executed under FAR 6.302-1, involves the continuation of prior Defense Health Program-funded studies performed by Dr. Erin Lavik’s laboratory at CWRU, which has demonstrated significant effectiveness of the synthetic platelet in reducing bleeding in animal models. The upcoming research aims to test the synthetic platelets in a large animal trauma model that closely replicates human, non-compressible injuries seen in military contexts, enabling comparisons with other hemostatic interventions. The laboratory is uniquely qualified for the project as the sole manufacturer and patent holder of the synthetic platelet, ensuring no other vendors can provide this specialized product. Although this is a sole source contract with no solicitation documents issued, interested parties may submit capability statements, including technical data and cost information, by the stated deadline for government consideration. However, the decision not to compete remains at the government’s discretion, and information submitted will only determine whether a competitive procurement is warranted. Submissions must be sent electronically by the specified date to the Naval Medical Logistics Command’s designated email address for evaluation.

General Info

Sole source $162,121 contract to CWRU for FDA synthetic platelet research in military trauma models.

NAICS

541711 - Research and Development in Biotechnology

Place of Performance

MD

Set-Aside

NONE

Documents

0

No documents available

Documents will appear here when they are available.

AI Contract Breakdown

Uniform Contract Format

No documents to break down

The breakdown needs solicitation documents. None were found from this contract's source.

Timeline

Posted

special-notice

Ready to pursue this opportunity?

Get full access to track this contract, build proposals with AI assistance, and manage your pipeline.

Organization & Contact Information

Show more
AgencyDepartment Of Defense → Naval Medical Logistics Command
ContactsNo contacts available
OfficeFORT DETRICK, MD, 21702-9203, USA
Office AddressFORT DETRICK, MD, 21702-9203, USA
ContactsNo contact information available

Full Description

Show more
The Naval Medical Logistics Command (NMLC) intends to award a sole source contract under the authority of FAR 6.302-1 to Case Western Reserve University (CWRU), 10900 Euclid Avenue, Cleveland, Ohio, 44106 to continue the Navy’s studies into developing a FDA-approved synthetic platelet to treat hemorrhage. The proposed research is a continuation of a previous study performed by a CWRU laboratory and funded by the Defense Health Program (DHP). Previous work has completed the research and development to demonstrate that the synthetic platelet is effective in significantly decreasing bleeding in a rat major femoral artery injury. Thus, the lab has already assembled an extensive team of trained scientists and technical staff capable of performing this important research. The study will perform testing of the synthetic platelets in a large animal model of trauma that mimics human trauma. The model used will mimic non-compressible injuries sustained by military personnel and permits direct comparison to other hemostatic interventional studies. The estimated value of the contract is $162,121.00. No other vendors are capable of performing this work because only the laboratory of Dr. Erin Lavik’s at CWRU has the synthetic platelets. They are the sole manufacturer of this product and have a patent pending. The proprietary nature of the platelets means that there are no other companies who have or could obtain the platelets. This Notice of Intent is not a request for competitive proposals and no solicitation document exists for this requirement. However, parties interested in responding to this notice will need to submit technical data, including cost, sufficient to determine capability. All capability statements received by the closing date of this synopsis will be considered by the Government. A determination by the Government not to compete based on responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement. All capability statements received by 9:00 AM Eastern Time, 5 JULY 2012 will be considered by the Government. Capability statements shall be submitted by e-mail ONLY as a Microsoft Word or Adobe PDF attachment to contact@example.gov.

Similar Contracts

Same NAICS industry code

Earlier notices in this NAICS code

Posted before this notice, open and closed

Ready to Pursue This Opportunity?

Get AI-powered intelligence on this solicitation and the ones like it

Every page of the solicitation package shredded into a compliance breakdown

AI-powered matching based on your capabilities and past performance

Competitor and incumbent history on the requirement

Automated alerts on amendments, Q&A deadlines, and award

Miguel
Hillary
Keith Deutsch
Christine

Join 750+ contractors already using CLEATUS